Neuca

Neuca EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Neuca (NEU.WA) as of Oct 22, 2026 is 18.16. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 14.05 — a change of 29.20% (higher).

EV/EBITDA

18.16

YoY

29.20%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Neuca is 2025 18.16 . EV/EBITDA (Enterprise Value to EBITDA) of Neuca was 2024 14.05 . It decreases by 29.20% higher compared to the previous year.

The Neuca EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
29.49 PLN
Jan 1, 2019
25.01 PLN
Jan 1, 2020
17.44 PLN
Jan 1, 2021
18.08 PLN
Jan 1, 2022
15.37 PLN
Jan 1, 2023
15.47 PLN
Jan 1, 2024
14.05 PLN
Jan 1, 2025
18.16 PLN
The Neuca EV/EBITDA history
YEAREV/EBITDAYoY
18.16+29.20%
14.05-9.14%
15.47+0.66%
15.37-15.00%
18.08+3.66%
17.44-30.28%
25.01-15.17%
29.49-0.72%
29.70+13.36%
26.20-14.76%
30.74-37.03%
48.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

EV/EBITDA (Enterprise Value to EBITDA) of Neuca is 18.16 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Neuca changed from 14.05 to 18.16, representing a 29.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Neuca since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Neuca with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Neuca

All Key Metrics — Neuca